Treatment of advanced prostatic cancer, resistant to conventional therapy, with aminoglutethimide.
Fifty-eight patients with advanced, progressing prostatic cancer resistant to conventional therapy have been assessed for their response to treatment with aminoglutethimide (A/G). Eleven men (19%) had objective regression of their disease while in a further eight (14%) progression of the disease was arrested. Median survival in the objective remitters (15 months) and in the group in whom stabilization of disease occurred (9.3 months) was significantly longer than in the non-remitting patients (4.7 months). The drug was well tolerated and no serious side-effects occurred. A/G appears to be a useful treatment in patients with advanced prostatic cancer resistant to conventional therapy.
D000368:Aged; D000616:Aminoglutethimide / Q000627:therapeutic use*; D002369:Castration; D003131:Combined Modality Therapy; D004967:Estrogens / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy
D004967:Estrogens; D000616:Aminoglutethimide